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ABSTRACT 
 
Inﬂammatory bowel disease (IBD) is a chronic inﬂammatory disorder of the intestinal tract 
whose etiology has not yet been fully elucidated. Available medicines for treatment of IBD are 
not universally effective and result in marked deleterious effects. This challenge has thus height-
ened the need for research in order to adopt new therapeutic approaches for the treatment of IBD. 
5-HT3 receptor antagonists have shown analgesic and anti-inflammatory properties in vitro and in 
vivo. Our aim was to investigate the effect of ondansetron, 5-HT3 receptor antagonist, in an im-
mune-based animal model of IBD, trinitrobenzene sulfonic acid (TNBS)-induced rat colitis and 
probable involvement of 5-HT3 receptors. 
Two hours after induction of colitis (instillation of 50 mg/kg of TNBS dissolved in 0.25 ml of 
ethanol 50 % v/v) to male Wistar rats, ondansetron (2 mg/kg), dexamethasone (1 mg/kg), meta-
chlorophenylbiguanide (mCPBG, 5 mg/kg), a 5-HT3 receptor agonist, or ondansetron + mCPBG 
were administrated intraperitoneally (ip) and continued daily for six days. The animals were sac-
rificed and distal colons were assessed macroscopically, histologically and biochemically 
[myeloperoxidase (MPO), tumor necrosis factor-alpha, interleukin-6 and interleukin-1 beta]. 
Ondansetron and dexamethasone resulted in a decrease in macroscopic and microscopic colonic 
damage significantly. In addition a dramatic reduction in MPO activity and colonic levels of in-
flammatory cytokines were seen. The protective effects of ondansetron were antagonized by con-
current administration of mCPBG. Our data suggests that the beneficial effects of ondansetron in 
TNBS-induced colitis could be mediated by 5-HT3 receptors. 
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INTRODUCTION 
The inﬂammatory bowel diseases (IBDs) 
include idiopathic, chronic, recurrent intesti-
nal disorders. Their complex pathogenesis is 
mostly represented by Crohn’s disease (CD) 
and ulcerative colitis (UC). Of the various 
forms of chronic inﬂammatory condition of 
the human bowels, IBD is the most common 
and the most serious (Podolsky, 1991). In 
spite of continuous medical advances, IBDs 
are still-incurable diseases. Genetic and en-
vironmental factors, impaired immunity, and 
microbial factors are believed to give rise to 
this inflammatory condition (Baumaqart and 
Sandborn, 2007; Kucharzik et al., 2006). 
IBD is characterized by massive cellular 
inﬁltrates and pertains to immunological ab-
normalities showing increasing numbers of 
CD4+ T lymphocytes, mast cells, neutro-
phils, and eosinophils (Forbes et al., 2004). 
Some medical therapies such as salicylates, 
glucocorticoids, and immunosuppressives 
have been administered for IBD (Sands, 
2000; Braus and Elliott, 2009); however, its 
treatment remained challenging. To clarify, 
difficulties such as low efficacy and high 
incidence of side effects, alongside unreach-
able remission, are the major limitations in 
treatment of IBD (Dubinsky, 2004). There 
is, therefore, a definite need for research to 
employ the new therapeutic approaches for 
IBD treatment. 5-Hydroxytryptamine (5-HT, 
serotonin) is a neurotransmitter and an im-
portant signaling molecule in the intestine 
(Gershon, 1999). It is also found in the im-
mune-inﬂammatory axis and affects the 
mammalian immune response (Kim et al., 
2000; Cloez-Tayarani et al., 2003). Intestinal 
inﬂammation may arise from a change in 5-
HT-producing enterochromafﬁn (EC) cells 
and an increase in 5-HT content associated 
with the pattern of IBD (Bishop et al., 1987; 
Coates et al., 2004). To date, multiple sero-
toninergic receptors have been identified. To 
illustrate, 5-HT3 receptor (5-HT3R) has been 
demonstrated to express in immune cells 
including T lymphocytes. It has also been 
found that 5-HT can modulate the T cells 
function through activation of 5-HT3R. T-
cell activation and proliferation, for exam-
ple, is potentiated by activation of 5-HT3Rs 
present on these cells (Fiebich et al., 2004b). 
Recently, there has been an increasing pro-
pensity for investigating cellular and molec-
ular mechanisms predisposing to IBD using 
of different animal models (Hibi et al., 
2002). So much attention has recently been 
devoted to TNBS model of colitis since it 
can exhibit the inflammation related to cyto-
kines secretion (Wirtz and Neurath, 2007). It 
is assumed that UC is associated with the 
enhancement of serotonin secretion (Coates 
et al., 2004). More to the point, an increase 
in 5-HT content and secretion resembling 
the pattern of UC was observed in TNBS 
model of colitis (Linden et al., 2003). On the 
other hand, amongst the various models of 
induction of colitis, TNBS model is effi-
ciently able to mimic both acute and chronic 
colitis resembling the human UC (Ajuebor 
et al., 2001). 
In order to prevent chemotherapy-
induced emesis, 5-HT3 receptor antagonists 
have been commonly used (Kris, 1994). Re-
cent findings also demonstrated new clinical 
indications for this class of medicines (Liu 
et al., 2011; McCleane et al., 2003). 5-HT3 
receptor antagonists, including tropisetron 
and ondansetron, were found to serve anti-
inﬂammatory property (Fiebich et al., 
2004a). Nonetheless, the complicated mech-
anisms for these impacts have not yet been 
completely identified. Fiebich et al. reported 
that lipopolysaccharide-stimulated secretion 
of tumor necrosis factor-α (TNF-α) was 
dose-dependently inhibited by ondansetron 
in human monocytes (Fiebich et al., 2004a). 
Moreover, preliminary data have shown that 
the intravenous injection of ondansetron has 
an analgesic affect in neuropathic pain 
(McCleane et al., 2003). These findings pro-
duce new mechanistic insights into anti-
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inﬂammatory activity of ondansetron that 
might be at least partly mediated through its 
effect on 5-HT3 receptors pathways.  
To date, no data are available on poten-
tial beneﬁcial effect of ondansetron in IBD. 
Present study sets out to assess the anti-
inﬂammatory property of ondansetron 
(through its effect on 5-HT3 receptors) upon 
colonic inﬂammation markers and to com-
pare the effects of ondansetron with dexa-
methasone as a reference drug and investi-
gate the probable involvement of 5-HT3Rs in 
protecting against colitis in TNBS-induced 
colitis in rats. 
 
MATERIALS AND METHODS 
Animals 
Male Wistar rats (250 ± 20 g, 12-week-
old) bred in animal house of School of 
Pharmacy, Isfahan University of Medical 
Sciences were used. Animals were housed in 
groups of 6, under controlled temperature 
(23 ±1 °C), relative humidity (55 ± 10 %), 
and lighting conditions (12/12 hours 
light/dark) and fed standard pelleted chow 
and water ad libitum. All experimental pro-
tocols were approved by the Animal Care 
Committee of the Isfahan University of 
Medical Sciences. 
 
Chemicals 
Dexamethasone was purchased from 
Iran Hormone Pharmaceutical Co. (Tehran, 
Iran). Ondansetron hydrochloride was do-
nated by Amin Pharmaceutical Co. (Tehran, 
Iran); metachlorophenylbiguanide (mPBG) 
and TNBS were purchased from Sigma (St. 
Louis, MO, USA). Hexadecyltrimethyl-
ammonium bromide (HTAB), aprotinin A, 
bovine serum albumin, phenylmethyl-
sulfonyl ﬂuoride, benzethonium chloride, 
ethylene diamine tetra acetic acid (EDTA), 
and Tween 20 were all purchased from Sig-
ma Chemical Company (St. Louis, MO, 
USA). TNF-α (ALPCO, USA), IL-1β 
(ALPCO, USA) and IL-6 (ALPCO, USA) 
kits were used for measurement of biochem-
ical variables. 
 
Grouping 
Animals were randomly divided into the 
following groups of 6 rats in each: (I) 
TNBS-control group: 2 hours subsequent to 
induction of colitis, normal saline was ad-
ministered intraperitoneally (ip); (II) normal 
group: rectal cannulation proceeded without 
induction of colitis, receiving normal saline 
(0.25 ml/rat) in lieu of TNBS; (III) Dexame-
thasone group: 2 hours subsequent to induc-
tion of colitis, dexamethasone (1 mg/kg) 
was administered ip (Minaiyan et al., 2012); 
(IV) Ondansetron group: 2 hours subsequent 
to induction of colitis, ondansetron (2 
mg/kg) was given ip (Saeki et al., 2001); (V) 
Meta chlorophenylbiguanide group: 2 hours 
after induction of colitis, meta chloro-
phenylbiguanide (mCPBG; 5 mg/kg), a 5-
HT3 receptor agonist, was given ip (Calla-
han and Cunningham, 1994); (VI) On-
dansetron + mCPBG group: 2 hours after 
induction of colitis, ondansetron and 
mCPBG were given simultaneously, ip. 
 
Induction of colitis 
Rats were fasted for 36 hours with free 
access to water before induction of colitis. 
Following assessment of their health, colitis 
was induced by means of method of Morris 
et al. (1989). Having performed light ether 
anesthesia, we positioned the rats on their 
right. TNBS (50 mg/kg; dissolved in 50 % 
ethanol), was then administered intracolon-
ically in a volume of 0.25 ml, via a polyeth-
ylene catheter inserted 8 cm proximal to the 
anus. Rats were positioned head-down for 2-
3 minutes to preclude immediate anal leak-
age of the instillate and thereafter returned 
to their cages with access to food and water 
ad libitum. Normal group was given an en-
ema of 0.25 ml of normal saline. 
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Measurment of body weight changes and 
diarrheal status 
Body weight was recorded for each ani-
mal during the experimental period (prior to 
the administration of TNBS and subsequent-
ly daily for 6 days). Percent of body weight 
loss was thereafter measured. In addition, 
the fecal output was scored using arbitrary 
criteria as follows: 1. Formed stools, 2. 
Loosed stools and 3. Diarrhea, which were 
assessed daily for 6 days. 
 
Macroscopic assessment  
Animals were sacriﬁced by means of 
ether inhalation on day 6. Their abdomen 
was opened and the appearance of colon was 
then examined. Distal colon was removed, 
opened longitudinally and gently cleaned of 
fecal content using normal saline and pro-
cessed for assessment by macroscopic, his-
tological scores and biochemical markers. 
For each specimen, distal colon wet weight 
(mg) (8 cm from the anus) and weight/ 
length ratio (mg/cm) were measured. Using 
scoring system depicted in Table 1 accord-
ing to Ballester et al. (2007), with some 
modifications, the severity of macroscopi-
cally visible colonic damage was scored. 
The intestinal segments were then divided 
longitudinally in 3-4 pieces and immediately 
frozen in liquid nitrogen for evaluation of 
biochemical variables. 
 
Ulcer area and percent of necrosis meas-
urement 
Using a digital camera (Canon IXUS 
130.Tokyo, Japan), The RGB (red, green, 
blue) photos (24-bits) of the rats’ colon was 
taken. The camera was positioned 20 cm 
above of the samples. Vertical and horizon-
tal rulers were fixed on the table. The hori-
zontal and vertical resolution of the images 
was 1934 and 2523 pixels, respectively. To 
provide a constant illumination, the images 
were taken at a shutter speed of 1/250 s us-
ing the external light source, by same inves-
tigator. All images were captured in a fixed 
setting of WB (Wight Balance) and bright-
ness.  
 
Table 1: Scoring criteria for assessment of  
macroscopic colonic injuries  
 
Adhesions 0 No adhesions 
1 Difficult dissection 
2 Visible adhesions 
3 ‘Wrapped’ intestine 
 
Obstruction  0 No obstruction 
1 Need for gentle manual 
cleaning 
2 Fecal impaction 
 
Thickening 0 Similar to uninflamed  
intestine 
1 Thicker than normal  
(∼1–2 mm) 
2 Much thicker than normal 
(>2 mm) 
 
Hyperemia    0 Similar to uninflamed intes-
tine 
1 Mild and generalized or 
intense but localized hy-
peremia 
2 Intense and localized hy-
peremia 
3 Frank hemorrhage 
 
Necrosis 0 No signs of necrosis 
1 Small areas of necrosis 
2 Patchy necrosis  
3 Focal necrosis <0.8 cm 
4 Focal necrosis >0.8 cm 
5 Extended necrotic lesion 
 
In order to analyze the images, image 
processing software (ImageJ) was em-
ployed. ImageJ is public domain Java image 
processing and analysis software inspired by 
NIH Image for the Macintosh (Ghosh et al., 
2004). It is able to display, edit, analyze, 
process, save and print 8–bit, 16–bit and 32–
bit photos. It can also calculate area and pix-
el value statistics of user-defined selections, 
measure distances and angles, make histo-
grams and support standard image pro-
cessing involving contrast manipulation, 
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sharpening, smoothing, edge detection and 
median filtering. Our pilot studies indicated 
that this image analysis program was much 
more accurate and convenient than previous-
ly-made manual processing (Minaiyan and 
Ghafghazi, 1999). Prior to taking photos, 
camera parameters and position had to be 
adjusted. The colon of the rat was gently 
pinched manually, so that the ulcer site was 
positioned at the intersection of the vertical 
and horizontal grid lines on the graphics ta-
ble. After taking photos, it was followed by 
the image processing. This includes 3 steps 
in the following order: 1. Preprocess, 
2. Noise reduction and 3. Analysis. Each 
image was devided in 3 segments: back-
ground, colon (raw wound, undamaged in-
tact colon), rulers (vertical – horizontal). In 
the preprocess step, the colon segmented 
from the background of graphic table by ap-
plying a color filter using the prior 
knowledge that the table used was green in 
color. Rulers and grid lines were thereafter 
utilized. The two regions containing the hor-
izontal (10 mm) and vertical (10 mm) rulers 
were firstly segmented and set on Image by 
the ability of ImageJ (Set Scale) to identify 
the horizontal and vertical gradation marks 
on the rulers to allow determination of the 
horizontal and vertical resolutions of the im-
ages in pixels per millimeter. The quality of 
image was enhanced by the Median 
(size = 5) and Gaussian (size = 5) filters in 
the noise reduction stage. Image was then 
ready for color threshold. Analysis stage in-
corporated color threshold and finally calcu-
lating the percent of necrosis [necrosis area 
is divided to total area based on 8cm of co-
lon (from the anus)] and ulcer area of colon 
sample (Figure 1).  
 
Microscopic assessment  
For microscopic assessment, colon sam-
ples were fixed in 10 % formalin, dehydrat-
ed, paraffin embedded processed, sliced into 
4 µm-thick sections and stained with H&E 
(haematoxylin and eosin). By means of a 
modified validated scoring system presented 
by Cooper et al. (1993) and Dieleman et al. 
(1998) total colitis index was then derived 
by summing 3 sub-scores (inflammation se-
verity, inflammation extent, crypt damage) 
on H&E-stained and coded sections. 
Pathologist blinded to the study evaluated 
the microscopic and histological scoring 
study. It was implemented by means of a 
Zeiss® microscope equipped with a Sony® 
color video camera for digital imaging. 
 
 
 
Figure 1: Measurement of ulcer area by ImageJ 
program. Horizontal and vertical charting rulers 
as horizontal and vertical scale were recognized 
and interpreted by the ImageJ. With regard to 
ulcer color differentiation, some template photo-
graphs with a series of red colors were applied 
in order to enable the program for recognition of 
ulcers and calculate the area automatically. 
 
 
Determination of MPO activity 
Using the modiﬁed method of Bradley et 
al. (1982), MPO activity, which is a bio-
chemical indicator of neutrophil infiltration 
into gastrointestinal tissue, was measured. 
Each segment was weighed and chopped in 
1 ml of 50 mM potassium phosphate buffer 
involving 0.5 % HTAB. Having chopped, 
we placed tissue in a homogenizing tube. 
The container was then rinsed with 2×1 ml 
HTAB in buffer solution. Afterwards, we 
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add more buffer in order to have a concen-
tration which was equivalent to 5 ml per 
0.1 g of colon tissue and homogenized 
(15,000 rpm) for 4×45 s at 1 min intervals. 
The homogenate was placed in a sample 
tube, sonicated in an ice bath for 10 s, sub-
jected to 3 cycles of freezing and thawing, 
and sonicated again for 10 s. The suspen-
sions were centrifuged (15,000 rpm for 
15 min in 4 °C). The supernatant thereafter 
decanted for assessment. The MPO activity 
was analyzed spectrophotometrically as fol-
lows: 0.1 ml of the supernatant was added to 
2.9 ml of 50 mM K3PO4 buffer (pH = 6.0) 
involving O-dianisidinedihydrochloride 
(0.167 mg/ml) and 0.005 % hydrogen perox-
ide. The absorbance of the reaction mixture 
was recorded at a wave length of 450 nm by 
means of a UV–Vis spectrophotometer. The 
data were reported as the change in absorb-
ance/min/mg colonic wet weight. 
 
Measurement of the IL-1β, IL-6 and TNF-
α levels in the rat colon 
Using enzyme-linked immunosorbent 
assay (ELISA) kit (ALPCO, USA), TNF-α, 
IL-1β and IL-6 levels in the inflamed colon 
tissues were determined as described earlier 
(Nacife et al., 2004). The colon tissue seg-
ments were weighed and processed in order 
to determine IL-1β, IL-6 and TNF-α content. 
Thereafter colon samples were homogenized 
in phosphate buffered saline (PBS; 
pH = 7.4) containing 0.4 M NaCl, 0.05 % 
Tween-20, 0.5 % bovine serum albumin, 
0.1 mM phenylmethylsulfonyl ﬂuoride, 
0.1 mM benzethonium chloride, aprotinin A 
20 KI, and 10 mM EDTA. They were then 
centrifuged at 12,000×g for 30 min at 4 °C, 
and ELISA was performed in order to assess 
the levels of IL-1β and TNF-α in the super-
natants. 
 
Statistical analysis  
Data analysis was performed using the 
SPSS statistical package (Version 17.0). 
Comparison between groups was made us-
ing one-way analysis of variance (ANOVA) 
with TUKEY as post hoc test. Non-
parametric data were analyzed by Mann-
Whitney U test. Results were reported as 
mean ± standard error of mean (SEM). A P-
value < 0.05 was considered significant. 
 
RESULTS 
Animals’ body weight and diarrheal status 
TNBS-treated rats showed loss of body 
weight after 6 days (P<0.001). Animals in 
ondansetron and dexamethasone-treated 
groups also experienced a significant loss of 
body weight in comparison with normal 
group; however, percent of body weight loss 
in these groups was significantly lower than 
TNBS-control group after 6 days (P<0.01) 
(Table 2).  
Figure 2 illustrates that in all 6 days, di-
arrheal status of TNBS-control group was 
significantly higher than that of normal 
groups (P<0.01). In comparison with normal 
group, dexamethasone and ondansetron-
treated rats showed a significant increase in 
the diarrhea index during the first 4 days af-
ter induction of colitis (P values are shown 
in Figure 2). However, diarrhea index di-
minished slowly from day 2 to 6 in these 
groups, and after day 4, no significant dif-
ference was observed in diarrheal status of 
aforementioned groups compared to that of 
normal group. Furthermore, there was no 
significant difference in the daily diarrheal 
status and percent of body weight loss be-
tween ondansetron-treated with dexame-
thasone-treated groups during the experi-
ment. mCPBG as a serotonin agonist could 
not alter the diarrheal status of TNBS-
treated rat; however, it nullified the thera-
peutic effects of ondansetron, suggesting a 
significant role for 5-HT3 receptors in diar-
rheal status of colitic rats. 
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Figure 2: Changes in diarrheal status before 
(day 0) and during 6 days of treatment after in-
duction of colitis (TNBS, 50 mg/kg) in rats. Val-
ues are means ± SEM (n=6). **P<0.01 and 
*P<0.05 compared with normal group. Dex= 
Dexamethasone; TNBS-control= TNBS-control 
group; Ond= ondansetron group; mCPBG= meta 
chlorophenylbiguanide group; Ond+mCPBG= 
ondansetron+metachlorophenylbiguanide group. 
TNBS= 2,4,6-trinitrobenzenesulfonic acid. The 
rats were checked daily for stool consistency (1. 
Formed stools, 2. Loosed stools and 3. Diar-
rhea). 
 
Assessment of macroscopic features 
Severe inflammation, hemorrhage, ulcer, 
necrosis and thickened colon wall were 
found 6 days following induction of colitis 
in TNBS-control group, whereas macro-
scopic features of colon was quite intact in 
normal group (Table 2). Ondansetron or 
dexamethasone significantly decreased ulcer 
severity and weight/length ratio (P<0.01) as 
compared to TNBS-control group. No sig-
nificant difference in aforementioned pa-
rameters was found between ondansetron 
and dexamethasone-treated groups. In addi-
tion, ulcer severity score (P<0.01) and 
weight length ratio (P<0.05) in ondansetron 
+ mCPBG-treated rats were significantly 
high as compared to ondansetron group. We 
found that ulcer area and percent of necrosis 
were significantly lower in dexamethasone 
and ondansetron group, than in TNBS-
control group. These macroscopic features 
were deteriorated significantly in on-
dansetron plus mCPBG-treated rats in com-
parison to ondansetron-treated rats (P<0.05). 
mCPBG exerted no effect itself upon macro-
scopic features of colitis.  
 
Assessment of histopathological features 
Histopathological assessment of colon 
tissued, exhibited a normal architecture with 
intact epithelium in colonic mucosa in nor-
mal group (Figure 3). We found however, a 
severe and intense transmural inflammation 
and/or diffuse necrosis, inflammatory granu-
lomas and submucosal neutrophils infiltra-
tion in 50 mg/kg-TNBS-control rats.  
Ondansetron and dexamethasone-treated 
groups underwent significant decreased his-
topathological alterations. These treatments 
brought about a decline in total colitis index 
in injurious colons (Table 2). Re-epitheli-
zation of the mucosal layer and reduced 
inﬂammatory cell inﬁltration in lamina pro-
pria were observed in these groups. In this 
regard, no significant difference was seen 
between ondansetron and dexamethasone 
groups. Concomitant administration of 
mCPBG and ondansetron, significantly ex-
acerbated histopathological aspects, com-
pared to ondansetron administration alone 
(p<0.01). No significant difference was 
found in microscopic features between 
mCPBG-treated animals and TNBS-control 
group. 
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Table 2: Macroscopic and histologic parameters of colitis induced by TNBS (50mg/kg) in rats. All treat-
ments were made daily for six days after induction of colitis.  
 
 
Group 
 
Colonic 
weight/length  
ratio 
(mg/cm) 
 
Body weight 
loss after  
6 days (%) 
 
Ulcer  
severity 
(0-15) 
 
Total colitis 
index  
(0-10) 
 
Ulcer  
area 
(cm2) 
 
Necrosis 
(%) 
Normal 64.8 ± 2.3 -1.9 ± 0.6 0.0 0.0 0.0 0.0 
TNBS-control 256.3 ± 9.5 7.7 ± 0.7 12.2 ± 0.6 9.9 ± 0.1 6.2 ± 0.1 51.5 ± 2.8 
Ond.  
(2mg/kg, ip) 
158.3 ± 14.3** 3.6 ± 0.1** 6.2 ± 1.1** 6.0 ± 0.2** 4.3 ± 0.5* 26.4 ± 4.1* 
mCPBG 
(5mg/kg, ip) 
252.1 ± 8.2 8.1 ± 0.8 11.5 ± 0.6 9.7 ± 0.1  6.1 ± 0.2 51.3 ± 3.2 
mCPBG+ Ond. 248.9 ± 29.2 7.9 ± 0.6 12.0 ± 0.4 9.6 ± 0.2 6.2 ± 0.3 50.8 ± 3.4 
Dex.  
(1mg/kg, ip) 
161.9 ± 25.9** 3.9 ± 0.3**  5.33± 1.4** 4.8 ± 0.8** 4.0 ± 0.7* 27.0 ± 7.9* 
TNBS= 2,4,6-trinitrobenzenesulfonic acid; Ond.= ondansetron; mCPG= meta-chlorophenylbiguanide; 
Dex.= dexamethasone; ip= intraperitoneal 
Values are means ± SEM; n=6. 
**P<0.01 and *P<0.05: Significant difference compared to TNBS-control group 
 
 
Assessment of MPO activity 
As can be noted in Figure 4, we observed 
that MPO activity, which is a marker for leu-
kocyte infiltration into the inﬂamed tissue, 
was conspicuously enhanced in the inflamed 
colon following the intrarectal TNBS admin-
istration. This result confirmed the histologi-
cal assessment indicating increased leukocyte 
inﬁltration. In addition, we found that on-
dansetron or dexamethasone treatment signif-
Figure 3: Microscopic presentation of TNBS-
induced colitis in rats (hematoxylin and eosin 
staining; original magniﬁcation 10×). (A) Nor-
mal group: Colon tissue with normal architec-
ture; (B) TNBS-control group: epithelial distor-
tion, architectural destruction of the crypts and 
inﬂammatory cell inﬁltrates; (C & D) Dexame-
thasone and ondansetron groups respective-
ly: mild to moderate mucosal and submucosal 
inflammation and mucosal inflammatory cell 
infiltrates; (E & F): mCPBG and mCPBG + 
ondansetron, respectively: destruction of mu-
cosal architecture and infiltration of neutro-
phils. TNBS= 2,4,6-trinitrobenzenesulfonic 
acid; mCPG= meta-chlorophenylbiguanide 
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icantly diminished the MPO activity level. A 
treatment with mCPBG as a 5-HT3 receptor 
agonist and ondansetron in tandem signifi-
cantly brought about a high MPO activity, as 
opposed to ondansetron treatment alone 
(P<0.05). Data from mCPBG group was not 
different from TNBS-control group (P values 
are shown in Figure 4). 
 
 
Figure 4: Changes in MPO activity of rat colon 
with TNBS-induced colitis. All treatments were 
made daily for 6 days. Ond.= ondansetron 
(2 mg/kg); Dex.= dexamethasone (1 mg/kg); 
mCPBG= meta chlorophenylbiguanide (5 mg/ 
kg); TNBS= 2,4,6-trinitrobenzenesulfonic acid (50 
mg/kg); MPO= myeloperoxidase. Values are pre-
sented as mean ± SEM, n=6. *P<0.05 vs. TNBS-
control group  
 
Assessment of cytokine profiles (TNF-α, IL-
6, IL-1ß) 
Colonic levels of TNF-α, IL-1ß and IL-6 
in TNBS-treated rats were assessed in differ-
ent groups and compared with TNBS-control 
group. As it is shown in Figures 5-7 the lev-
els of cytokines were significantly lower in 
rats treated with either ondansetron or dexa-
methasone. In the group treated with the co-
administration of ondansetron and mCPBG, 
the levels of these values were significantly 
higher than the group taken exclusively on-
dansetron (P<0.05 for TNF-α and IL-6, 
P<0.01 for IL-1ß). No significant difference 
was found in TNF-α, IL-1ß and IL-6 levels 
between ondansetron and dexamethasone-
treated animals. mCPBG-treated group did 
not show any significant changes in the con-
tent of these inflammatory cytokines, as 
compared to TNBS-control group. 
 
 
Figure 5: Colonic TNF-α level of rats with TNBS-
induced colitis quantified by ELISA. Ond.= on-
dansetron (2 mg/kg); Dex.= dexamethasone 
(1 mg/kg); mCPBG= metachlorophenylbiguanide 
(5 mg/kg); TNBS= 2,4,6-trinitrobenzenesulfonic 
acid (50 mg/kg); TNF-α= tumor necrosis factor-
alpha. Values are presented as mean ± SEM, 
n=6. *P<0.05 vs. TNBS-control 
 
 
 
Figure 6: Colonic IL-1β level of rats with TNBS-
induced colitis quantified by ELISA. Ond.= on-
dansetron (2 mg/kg); Dex.= dexamethasone 
(1 mg/kg); mCPBG= metachlorophenylbiguanide 
(5 mg/kg); TNBS= 2,4,6-trinitrobenzenesulfonic 
acid (50 mg/kg); IL-1β= interleukin-1 beta. Values 
are presented as mean ± SEM, n=6. *P<0.01 vs. 
Normal group; #P<0.01 vs. TNBS- control group 
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Figure 7: Colonic IL-6 level of rats with TNBS-
induced colitis quantified by ELISA. Ond.= on-
dansetron (2 mg/kg); Dex.= dexamethasone 
(1 mg/kg); mCPBG= metachlorophenylbiguanide 
(5 mg/kg); TNBS= 2,4,6-trinitrobenzenesulfonic 
acid (50 mg/kg); IL-6= interleukin-6 .Values are 
presented as mean ± SEM, n=6. *P<0.05 vs. 
TNBS-control 
 
DISCUSSION 
It is interesting to note that the present 
study is the first one indicating alleviation of 
immune-based animal model of IBD; TNBS-
induced colitis in rats by ondansetron. On-
dansetron healed colonic macroscopic and 
histological damages, reduced levels of pro-
inflammatory cytokines and diminished ele-
vated tissue MPO. On the grounds that con-
current administration of mCPBG negates 
these effects, it can be inferred that 5-HT3 
receptor contributes to the protection pro-
duced by ondansetron. 
In spite of the fact that ondansetron, a po-
tent antiemetic, has commonly been adminis-
tered in order to ameliorate vomiting caused 
by surgery or chemo/radiation therapies, new 
potential applications have been suggested 
for this drug (Kris, 1994; Liu et al., 2011; 
McCleane et al., 2003). It was also suggested 
that ondansetron, which is a selective 5-HT3 
receptor antagonist, exerts antiphlogistic and 
analgesic activities (Faerber et al., 2007). 
TNBS method is one of the most common 
models of induction of colitis. This model 
provides a simple process, reproducible co-
lonic damage and long-lasting damage along 
with inflammatory cell infiltration and ulcers. 
It is efficiently able to mimic the pattern of 
inflammation with human ulcerative colitis 
(Zheng et al., 2000). Considering the fact that 
the serotonin content increase during TNBS-
induced colitis, it is likely to be beneficial 
and suitable for analyzing the drugs affecting 
serotonin pathway in intestinal inflammation 
(Linden et al., 2003). Taking into account of 
the immune system involvement, which is a 
considerable similarity of TNBS-induced co-
litis with human ulcerative colitis, serves a 
pivotal role in the pathogenesis of IBD 
(Wirtz and Neurath, 2007). TNBS model 
could activate both Th1 and Th2 responses 
(Dohi and Fujihashi, 2006) and mimic both 
acute and chronic phases of colitis based on 
experiment period (Ajuebor et al., 2001). 
Present study was designed on a six-days-
experiment in order to investigate the effect 
of daily administration of ondansetron upon 
TNBS-induced colitis. The time period of 
experiment adopted in present study is simi-
lar to the previous studies conducted on the 
model of TNBS-induced chronic inﬂamma-
tion in the rat (Morris et al., 1989).  
It has been demonstrated that an increase 
in the number of enterochromaffin (EC) cells 
and in 5-HT content is associated with intes-
tinal mucosal inflammation such as ulcerative 
colitis (Coates et al., 2004). It is also worth 
noting that serotoninergic receptors were 
found in immune cells such as macrophages, 
a principle source of proinﬂammatory cyto-
kines IL-1, IL-6, and TNF (Fiebich et al., 
2004b). Owing to the strategic location of 
EC, it is possible to infer that 5-HT serves a 
key role in inﬁltration and activation of mac-
rophages in intestinal inﬂammation.  
Linden et al. (2003) observed that an in-
crease in the bioavailability of 5-HT from 
mucosal epithelial cells affected TNBS-
induced colitis. The authors also reported that 
EC cell hyperplasia occured during inﬂam-
mation and SERT expression was downregu-
lated in TNBS-induced colitis. These findings 
are consistent with those of study conducted 
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on rectal biopsy specimens of patients with 
ulcerative colitis (Coates et al., 2004). In ad-
dition Magro et al. (2006) reported the in-
crease in 5-HT levels in the inflamed colon in 
TNBS-induced colitis may result from mast 
cell infiltration. 
Releasing cytokines by intestinal im-
munocytes can activate adjacent EC cells for 
5-HT secretion. This increased 5-HT secre-
tion via a positive feedback mechanism, con-
sequently, results in activation of more 5-HT3 
receptors on EC cells (Gebauer et al., 1993). 
More to the point, serotonin also is secreted 
by immune cells. As a consequence, this ex-
ogenously added serotonin augments T-cell 
proliferation (Fiebich et al., 2004b). It is evi-
dent that T cells serve a crucial role in patho-
genesis of IBD. Not only does an activation 
of Th1 cell bring about a secretion of the pro-
inﬂammatory cytokines, but also it stimulates 
tissue macrophages to liberate additional pro-
inﬂammatory cytokines (e.g. TNF-α, IL-1β, 
IL-6, IL-8, and IL-12), nitric oxide and reac-
tive oxygen species (Cloez-Tayarani and 
Changeux, 2007). These, in turn, cause tissue 
damage in IBD. Due to the fact that on-
dansetron inhibits T-cell proliferation (Vega 
et al., 2005), it can be inferred that on-
dansetron can reduce T-cell induced tissue 
damage in IBD. Furthermore, ondansetron, 
which is an antagonist of 5-HT3 receptor, 
modulates 5-HT secretion from EC cells. In 
addition, a decrease in the 5-HT content gives 
rise to lower number of activated macrophag-
es, the main proinﬂammatory cytokines 
source through their serotoninergic receptors 
(Cloez-Tayarani and Changeux, 2007).  
Amongst the intestinal immunomodulato-
ry factors, cytokines are believed to serve a 
fundamental role. To clarify, an imbalance 
between proinflammatory and anti-inflam-
matory cytokines contributes to the patho-
genesis of IBD. Proinflammatory cytokines 
(e.g., TNF-α, IL-1β and IL-6) released from 
macrophages, neutrophils and endothelial 
cells are overproduced in TNBS-induced co-
litis (Hosseini-Tabatabaei et al., 2009) and in 
human IBD (Rahimi et al., 2007). What 
should also be considered is that they can re-
sult in secretion of other cytokines, arachi-
donic acid metabolites and lytic enzymes and 
in turn, develop edema, fibrosis and necrosis 
(Maunder, 2000). In present study, we ob-
served that the content of these proinflamma-
tory cytokines augments as a result of follow-
ing TNBS instillation. Our findings indicated 
that ondansetron alleviated the colonic profile 
of these mediators. This result is perhaps due 
to inhibition of their synthesis or release. In 
vivo and in vitro studies confirmed that 5-
HT3 receptor antagonists possess anti-
inflammatory properties. Seidel et al. (2008) 
reported that these antagonists inhibited sero-
tonin-induced release of PGE2 from synovial 
cells. Lipopolysaccharide-induced TNF-α 
release, in human monocytes was dose-
dependently inhibited by ondansetron 
(Fiebich et al., 2004a). Additionally, Hrycaj 
et al. (2004) argued that patients with chronic 
inflammatory joint disease took advantage 
from 5-HT3 receptor antagonists.  
On the other hand, ondansetron, which is 
a 5-HT3 receptor antagonist, is likely to re-
duce the proinﬂammatory cytokine release by 
blocking the serotoninergic receptors of in-
testinal macrophages. Vega et al. (2005) re-
ported that the molecular target for the im-
munosuppressive activity of 5-HT3 receptor 
antagonists may be independent of its binding 
to 5-HT3 receptor. They said different T-cell 
suppression proﬁles of these antagonists may 
imply that their effects are mediated via 
pathways other than 5-HT3. However, based 
on our finding, the beneﬁcial effects of on-
dansetron upon colonic profile of cytokines 
in TNBS-induced colitis (an immune-based 
animal model of IBD with enhancement of 
serotonin content), are at least partly mediat-
ed through its effects in a receptor-dependent 
fashion.  
MPO refers to an enzyme which is dis-
tributed mostly in neutrophils and to a lesser 
extent in monocytes and macrophages. Its 
activity has been a marker used for assess-
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ment of neutrophil infiltration to the site of 
inflammation in both human and experi-
mental models of IBD (Esmaily et al., 2009). 
In the present study, elevated MPO activity in 
TNBS-treated rats was considerably attenuat-
ed by ondansetron. The plausible explanation 
is that diminution of MPO level by on-
dansetron is due to its ability to decline neu-
trophil infiltration to the inflamed tissue. 
Therefore, it may preclude the release of 
components deteriorating inflammatory con-
ditions. 
Neurogenic inﬂammation can be associ-
ated with colitis (Hassani et al., 2005). In ad-
dition, Faerber et al. (2007) found that sub-
stance P-induced neurogenic inflammation 
was associated with 5-Hydroxytryptamine (5-
HT) through acting at 5-HT3 receptors on 
capsaicin-sensitive fibers. 
It can be also inferred that the effects of 
ondansetron in experimental rat colitis may 
be at least partly explained by its ability to 
block 5-HT-induced inflammatory neuropep-
tide liberation. 
We found that mCPBG neutralized the 
protective effect of ondansetron on TNB-
induced colitis which acts through 5-HT3 re-
ceptors. This, in turn, can antagonize the in-
fluence of serotonin highly produced in colon 
over the course of inflammation. Animal 
treated with mCPBG experienced a colitis 
which was comparable to that of TNBS- con-
trol group. This might result from the severity 
of colitis reached its peak at the day of evalu-
ation of colon damage and thus no more se-
verity could be caused by mCPBG, a selec-
tive 5-HT3 receptor agonist. In addition, it 
can be inferred that there is the maximum 
level of involvement of serotonin pathway in 
TNBS-induced colitis and the administration 
of mCPBG as a potent 5-HT3 agonist, cannot 
further aggravate colitis through activation of 
this pathway.   
In conclusion, we found that ondansetron 
reduced colonic damage, neutrophil inﬁltra-
tion and colonic levels of pro-inﬂammatory 
cytokines, in the TNBS model of rat colitis, a 
common employed preclinical model of IBD, 
with an activity comparable to that of dexa-
methasone. In addition clinical efficacy of 
ondansetron, as an analgesic agent in patients 
with chronic inﬂammatory joint diseases has 
been documented. Therefore, it is possible 
that some anti-inflammatory effects of on-
dansetron upon colonic damage in TNBS-
induced colitis are at least partly mediated 
through its effects on 5-HT3 receptor. Con-
sidering the low incidence of adverse effects 
of ondansetron, it is inferred that IBD pa-
tients could benefit from 5-HT3 antagonists 
therapy. However, additional randomized 
clinical trials are warranted to establish the 
therapeutic usefulness of this drug for treat-
ment of IBD as an add-on therapy.  
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